Analysts Anticipate Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to Announce -$0.97 EPS

Share on StockTwits

Brokerages forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will post earnings per share (EPS) of ($0.97) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Adamas Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.10) and the highest estimate coming in at ($0.82). Adamas Pharmaceuticals posted earnings of ($1.26) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 23%. The firm is expected to report its next earnings results on Thursday, August 1st.

On average, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($3.77) per share for the current fiscal year, with EPS estimates ranging from ($4.29) to ($3.46). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.42) per share, with EPS estimates ranging from ($2.80) to ($2.12). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.13) by $0.05. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. The firm had revenue of $11.67 million for the quarter, compared to analyst estimates of $12.78 million.

ADMS has been the topic of several research reports. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Mizuho reissued a “buy” rating and set a $37.00 target price on shares of Revance Therapeutics in a research note on Wednesday, April 24th. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. Finally, ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $18.91.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Alps Advisors Inc. increased its holdings in Adamas Pharmaceuticals by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 66,026 shares of the specialty pharmaceutical company’s stock worth $469,000 after purchasing an additional 2,860 shares during the period. Advisor Group Inc. increased its holdings in Adamas Pharmaceuticals by 252.0% during the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 4,510 shares during the period. BNP Paribas Arbitrage SA purchased a new stake in Adamas Pharmaceuticals during the 1st quarter worth about $33,000. PNC Financial Services Group Inc. purchased a new stake in Adamas Pharmaceuticals during the 1st quarter worth about $43,000. Finally, Barclays PLC increased its holdings in Adamas Pharmaceuticals by 87.6% during the 4th quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 8,118 shares during the period. 76.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMS traded down $0.02 during mid-day trading on Wednesday, hitting $5.99. 881,349 shares of the stock were exchanged, compared to its average volume of 307,254. The firm’s fifty day moving average price is $5.37. Adamas Pharmaceuticals has a 1-year low of $4.20 and a 1-year high of $29.49. The company has a current ratio of 7.03, a quick ratio of 6.86 and a debt-to-equity ratio of 2.00. The company has a market cap of $164.91 million, a P/E ratio of -1.23 and a beta of 1.72.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Recommended Story: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.